Symbol
|
MZPLTQ | P319TQ | P308TQ | NGFLTQ | P322TQ | VDALTQ | VBMLTQ | VXULTQ | WEVLTQ | RMASRV | RMAJLV | WXNLTQ | EOJRCH | RMABXV | ICOEFG | NELRCH | YOTLTQ | NPYRCH | RMBWDV | RMAVSV |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nom | Multi Reverse Convertible | Multi Reverse Convertible | Multi Reverse Convertible | Multi Reverse Convertible | Multi Reverse Convertible | Worst of Reverse Convertible | Worst of Reverse Convertible | Multi Reverse Convertible | Multi Reverse Convertible | Multi Vonti | Multi Vonti | Multi Reverse Convertible | Worst of Callable Reverse Convertible | Multi Vonti | Reverse Convertible | Worst of Reverse Convertible | Worst of Callable Reverse Convertible | Worst of Callable Reverse Convertible | Multi Vonti | Multi Vonti |
Sous-jacent
|
Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / Zurich Insurance Group AG | Compagnie Financière Richemont SA / Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG | Lonza Group N / Novartis Sandoz Basket / Roche AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / UBS Group AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Swiss RE AG / UBS Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG | Compagnie Financière Richemont SA / Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Zurich Insurance Group AG | Nestlé S.A. / Novartis Sandoz Basket / Roche AG / Zurich Insurance Group AG | Nestlé / Novartis / Roche GS | Nestlé / Novartis / Roche GS / Zurich | Novartis / Roche GS / Swiss Life / Zurich | Nestlé / Novartis / Roche GS | Novartis AG / Sika AG / Swisscom N / Zurich Insurance Group AG | Nestlé / Novartis / Roche GS / UBS / Zurich | Holcim AG / Kühne & Nagel Intl. AG / Nestlé S.A. / Novartis AG / Roche AG |
Emetteur
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Échéance
|
07.07.2025 | 08.09.2025 | 07.10.2025 | 07.10.2025 | 23.12.2025 | 16.09.2025 | 30.09.2025 | 11.07.2025 | 31.03.2028 | 10.02.2026 | 10.06.2025 | 30.06.2028 | 14.01.2026 | 12.10.2026 | 03.11.2028 | 03.11.2025 | 24.11.2027 | 02.02.2026 | 27.07.2026 | 23.02.2026 |
Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Prix d'exercise
|
58,00 | 58,64 | 54,62 | 54,62 | 66,90 | 162,13 | 53,41 | 59,18 | 49,63 | 183,53 | 86,32 | 179,73 | 61,12 | 65,70 | - | 339,52 | 63,075 | 360,18 | 60,97 | 159,74 |
rendement max. p.a. | 91,41% | 53,61% | 45,83% | 44,38% | 27,71% | 0,47% | 0,09% | 7,50% | 4,62% | 6,36% | 21,49% | 6,18% | 5,20% | 6,38% | - | 2,57% | 4,85% | 6,29% | 8,45% | 16,46% |
Demande | 97,19 | 95,23 | 94,58 | 95,04 | 96,83 | 101,06 | 100,69 | 99,09 | 99,61 | 100,20 | 96,90 | 94,54 | 99,36 | 96,80 | 104,13 | 102,21 | 99,40 | 99,58 | 96,90 | 90,10 |
Offre | 97,99 | 96,03 | 95,38 | 95,84 | 97,63 | 101,87 | 101,50 | 99,89 | 100,41 | 103,00 | 99,90 | 95,34 | 100,16 | 99,80 | - | 103,03 | 100,20 | 100,38 | 99,70 | 91,30 |